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Objectives: A study found screening (with rapid plasma reagin (RPR)) pregnant women for maternal syphilis
was cost-effective in Mwanza, Tanzania. Recently, four rapid point-of-care (POC) syphilis tests were
evaluated in Mwanza, and found to have reasonable sensitivity/specificity. This analysis estimates the relative
cost-effectiveness of using these POC tests in the Mwanza syphilis screening intervention.
Methods: Empirical cost and epidemiological data were used to model the potential benefit of using POC tests
instead of RPR. Reductions in costs relating to training, supplies, and equipment were estimated, and any
changes in impact due to test sensitivity were included. Additional modelling explored how the results vary
with prevalence of past infection, misclassified RPR results, and if not all women return for treatment.
Results: The cost-effectiveness of using POC tests is mainly dependent on their cost and sensitivity for high titre
active syphilis (HTAS). Savings due to reductions in training and equipment are small. Current POC tests may
save more disability-adjusted life years (DALYs) than the RPR test in Mwanza, but the test cost needs to be
,US$0.63 to be as cost-effective as RPR. However, the cost-effectiveness of the RPR test worsens by 15% if its
HTAS sensitivity had been 75% instead of 86%, and by 25–65% if 20–40% of women had not returned for
treatment. In such settings, POC tests could improve cost-effectiveness. Lastly, the cost-effectiveness of POC
tests is affected little by the prevalence of syphilis, false RPR-positives, and past infections.
Discussion: Although the price of most POC tests needs to be reduced to make them as cost-effective as RPR,
their simplicity and limited requirements for electricity/equipment suggest their use could improve the
coverage of antenatal syphilis screening in developing countries.
M
any developing countries continue to have high syphilis
prevalences,1 with maternal syphilis contributing to
substantial perinatal morbidity and mortality world-
wide.2 However, even though antenatal syphilis screening can
avert these adverse pregnancy outcomes,3 and is cost-effective,4–
8 less than 40% of women attending antenatal services in sub-
Saharan Africa receive syphilis screening and treatment.6 9–12
The low screening and treatment coverage is partly due to
limitations of the rapid plasma reagin (RPR) test: it is only
useable on serum, requires refrigeration, and has low accuracy
in settings with insufficient training or facilities.10 13 14 In
addition, long delays between testing and treatment due to
batch testing, waiting for serum to separate, or sending tests to
central laboratories result in many women not returning/
staying for treatment.6 10 15 In light of this, the Sexually
Transmitted Diseases Diagnostics Initiative (SDI) in the
World Health Organization (WHO) has promoted the develop-
ment, evaluation and application of simple rapid point-of-care
(POC) tests for diagnosing syphilis in resource-constrained
settings.16 In so doing, it was hoped a test would be developed
that could help increase the coverage of antenatal screening
and treatment in sub-Saharan Africa.
In 2002, six commercially available POC tests were evaluated
by SDI.16 The evaluated tests were similar to treponemal tests
(Treponema pallidum haemagglutination assay (TPHA) or
Treponema pallidum particle agglutination assay (TPPA)) in that
they are highly specific, but once positive, they remain so for
life.16 RPR, in contrast, mainly detects syphilis infection, but is
not very specific.17 18 However, there are a number of
advantages to the new POC tests when compared to RPR and/
or TPHA/TPPA: they require less or no equipment, minimal
training and support, are easier to read, remain stable at room
temperature, and can be used on whole blood. This has raised
the question of whether these more expensive POC tests could
improve existing antenatal syphilis screening programmes.
A previous study in Mwanza, Tanzania, found screening
(with RPR) and treating pregnant women for maternal syphilis
was highly cost-effective for averting adverse birth outcomes.4
To explore the potential role of POC tests in antenatal syphilis
screening interventions, this paper uses data from this study
and an SDI evaluation of four syphilis POC tests in Mwanza19 to
model the cost-effectiveness of using POC tests in this
intervention. The model first compared the projected cost-
effectiveness of using POC tests with the current RPR screening
strategy used in Mwanza, and then explored how the results
would vary in settings: with different levels of past infection;
where the RPR test is less accurate; or where fewer women
receive treatment due to delays between testing and treatment.
METHODS
Cost-effectiveness of intervention with RPR test
From July 1998 to June 1999, 9713 women were screened for
maternal syphilis at the antenatal clinic in Mwanza, of which
696 (7.2%) were RPR positive and treated. The number of
women treated for high titre active syphilis (HTAS) (RPR >1:8
and TPHA positive), the only stage shown to be associated with
adverse birth outcomes in this setting,20 was estimated to be
187.3 21 However, 30 cases were missed due to the clinic RPR
Abbreviations: ANC, antenatal clinic; DALY, disability-adjusted life year;
HTAS, high titre active syphilis; POC, point-of-care; RPR, rapid plasma
reagin; SDI, Sexually Transmitted Diseases Diagnostics Initiative; TPHA,
Treponema pallidum haemagglutination assay; TPPA, Treponema pallidum
particle agglutination assay; WHO, World Health Organization
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test having a lower sensitivity for HTAS (86.2%) than the
laboratory based RPR test used to assess its accuracy.21 The
impact of the intervention was estimated in terms of disability-
adjusted life years (DALYs) saved, where DALYs are defined as
the sum of years of life lost due to premature mortality and
years lived with disability adjusted for severity. Based on the
detailed calculations by Terris-Prestholt et al4 and only
considering adverse birth outcomes, this intervention saved
1321 DALYs (7.1 DALYs saved per HTAS case treated) if
stillbirth is considered a full life lost and the Tanzanian life
expectancy is used, at an economic cost of US$12.0 per DALY
saved (2005 US$). In this analysis, modelling is used to
estimate how the cost-effectiveness of this intervention would
have changed if they had used syphilis POC tests over this
period.
Effectiveness of intervention with POC test
This study only considers the impact achieved from averting
adverse birth outcomes. For this reason, and because only
HTAS has been shown to be associated with adverse birth
outcomes in this setting,20 the impact analysis is only concerned
with the number of HTAS treated when different POC tests are
used.
In Mwanza, some HTAS cases were not treated because of the
reduced sensitivity of the clinic RPR test.21 If the TPHA test had
been used then all HTAS cases could have been diagnosed and
treated.20 As with the TPHA test, all available syphilis POC tests
are treponemal specific, but have reduced sensitivity compared
to the TPPA/TPHA test when used on serum.16 If the sensitivity
(Sr) and specificity (Spr) of the POC test compared to TPHA is
known, the number of women that would test positive with a
POC test (Nr) can be estimated from the number positive with
the TPHA test (NTPHA):
Nr = NTPHASr+(12Spr)(N2NTPHA) Equation 1
where N is the number of women screened. If the ratio between
the TPHA and RPR prevalence is known (h) then the number
that will test positive with a POC test can be estimated from the
number testing RPR positive (NRPR) in laboratory conditions by
adapting equation 1:
Nr = hNRPRSr+(12Spr)(N2hNRPR) Equation 2
Because of their reduced sensitivity, POC tests may not
diagnose all HTAS cases, with the number positive (Nr
Hi) being:
Nr
Hi = NHiSr
Hi Equation 3
where NHi is the number of HTAS cases in the screened
population and Sr
Hi is the sensitivity of the POC test for HTAS.
Because all RPR positive women were treated by the Mwanza
intervention, equations 2 and 3 can be used to estimate the
number of women and HTAS cases that would have been
treated with the POC test in Mwanza. Using the data presented
by Terris-Prestholt et al4 on the DALYs saved per HTAS case
treated (DALYtan), this can then be used to estimate the DALYs
saved.
Cost of intervention with POC test
From the study by Terris-Prestholt et al,4 a cost function for the
total economic cost of the existing intervention using RPR tests
can be obtained:
COSTRPR = ST+(Es+Ec+Ef)+T+(Dd+Dt+Do)+(Pl+Po)+R Equation 4
where all variables are defined in table 1. This cost function
was adapted to model the costs of using POC tests (2005 US$).
The model assumed the following aspects of the screening
intervention would have changed if POC tests had been used:
lab personnel would have required less training; less or no
equipment would have been needed; and the number of
women treated would have changed depending on the
sensitivity/specificity of the POC tests. Therefore, the cost of
using POC tests (COSTr) is estimated as:
COSTr = ST+(EcdE)+TdT+(Ddr+Dtr+Do)+(PldP+Po)+RdR Equation 5
where most parameters are defined as before, although Es and
Ef are not needed because POC tests do not require a shaker or
fridge, and Drt and D
r
d are the test and drug costs when using
POC tests:
Drt = CrN(1+dW) Equation 6
Drd = Cdrug[NRPRhSr+(12Spr)(N2NRPRh)] Equation 7
where Cdrug is the penicillin cost per woman treated, Cr is the
POC test cost, and dW is the relative wastage of POC tests.
Model parameters
The model was mainly parameterised using data from three
studies undertaken in Mwanza, with uncertainty ranges being
assigned to most model inputs (table 1). Cost and intervention
output data were obtained for 1998–1999 from Terris-Prestholt
et al.4 Data on the accuracy of the clinic RPR test compared to
the RPR test undertaken at a reference laboratory (table 1), and
the number of screened women that would have tested positive
with a laboratory based RPR or TPHA test, were obtained from
a prospective cohort study undertaken in 1997–1999.3 21
Lastly, sensitivity/specificity estimates for the four syphilis
POC tests when compared to the TPPA test undertaken in a
laboratory setting were obtained from an evaluation of these
tests undertaken in Mwanza in 200419 (table 1 and appendix 1:
to view appendices 1-6 visit the STI website—http://www.
stijournal.com/supplemental). The tests were evaluated on
blood in an antenatal clinic (ANC) setting and on blood and
serum in a laboratory setting. The ANC results were used to
estimate the impact of using POC tests on blood, and because of
a lack of other data the laboratory results were used to estimate
the impact of using the tests on serum. The sensitivity of the
tests for HTAS was also evaluated, but only on 13–20 HTAS
samples. Table 1 also includes the current WHO procurement
cost for the POC tests. The POC tests were also assumed to need
less training and supply deliveries, and no centrifuge was
needed if the tests were used on whole blood.
Cost-effectiveness of intervention with POC test
Using equations 3 and 5, the cost-effectiveness of using a
specific POC test (CEr) can be estimated by dividing the
estimated cost of the intervention while using that POC test by
projections of the DALYs saved from averting adverse birth
outcomes:
Because of uncertainty in many model inputs, an uncertainty
analysis was undertaken on the projected cost (COSTr) and
impact (Nr
Hi) of using each POC test. Uniform distributions
were associated with the uncertainty intervals for most model
parameters except the sensitivity and specificity of the POC
tests which were assumed to be normally distributed. For each
test, random sampling of the parameter uncertainty ranges was
used to obtain 500 parameter sets. These produced paired
estimates for the impact and cost of the intervention. The
distribution obtained was used to obtain uncertainty bounds
for the intervention’s cost-effectiveness, which was compared
to the cost-effectiveness of the RPR test.4 A multi-linear
regression analysis was then undertaken to determine which
parameters contributed most to the uncertainty in the cost-
effectiveness projections.
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Threshold cost of POC test
The threshold cost (Cr
*) at which a POC test becomes as cost-
effective as the RPR test can be obtained from equation 8 to
give (see appendix 3 for the derivation):
For each POC test, the cost-threshold was calculated for
different HTAS sensitivities while other parameters were varied
to obtain the lowest cost-threshold at that sensitivity.
Sensitivity analysis to generalise to other settings
To generalise the results of this analysis to other settings, the
effect of variations in key parameters on the cost-effectiveness
of using the RPR or Bioline test (on blood) was explored.
Firstly, many women screened with the RPR test do not
receive treatment at their initial visit6 11 12 15 22 or do not wait
long enough for treatment, and so the cost-effectiveness of the
RPR test was estimated for different return rates (60–
80%).6 10 11 22 Secondly, because of the difficulty in interpreting
RPR test results in clinic settings11 13 14 and the frequent
occurrence of RPR biological false positives,13 17 18 23 the cost-
effectiveness of the RPR test was estimated for different
sensitivities to HTAS (75–100%),11 14 and for different preva-
lences of biological false positives (NRPR was varied between
563–130113 17). In contrast, the cost-effectiveness of the POC
test was estimated for different prevalences of old infection by
varying the ratio h between 104–188%.17 24 25 Lastly, the cost-
effectiveness of both tests was estimated for a wide range of
syphilis prevalences (5–21%).
The combined effect of these sensitivity analyses on the cost-
threshold for each POC test was analysed by incorporating the
return rate for the RPR test into equation 9.
RESULTS
Cost-effectiveness of POC tests
The estimated cost-effectiveness of using the four syphilis POC
tests on whole blood or serum are shown in table 2. The results
show that all POC tests, except the Determine test, will on
average result in more DALYs saved from averting adverse birth
outcomes than the RPR test. This is due to their higher
sensitivity for HTAS. However, because of the high cost of each
POC test, they all result in higher costs, about 6% greater with
Bioline test, 21–23% with Visitect and Syphcheck tests, and 36–
39% with Determine test. This results in all POC tests, except
Bioline, being less cost-effective than the RPR test (ranging
from 15–41% higher cost per DALY saved than RPR). In
contrast, although our projections suggest the Bioline test is on
Table 1 Model parameters for estimating the cost-effectiveness of the POC test. Cost estimates are in 2005 US$
Model parameters Symbol Value used Reference/source
Cost parameters for RPR intervention
Start up cost ST $ 760.0 4
Shaker cost Es $ 111.3 4
Centrifuge cost Ec $ 171.8 4
Fridge cost Ef $ 69.0 4
Training cost T $ 125.9 4
Total drug cost Dd $ 409.2 4
Total RPR test cost Dt $ 3640.7 4
Cost of other supplies Do $ 4509.0 4
Cost of laboratory staff Pl $ 2156.3 4
Cost of medical and other staff Po $ 3720.4 4
Cost of transport for requisitions R $ 158.0 4
Total cost of intervention COSTRPR $ 15,831.2 4
Additional cost parameters for POC test intervention
Cost per POC test Cr Bioline $0.47, Syphchek
and Visitect $0.75,
Determine $1.00
Cost through WHO in 2005
Cost of penicillin per woman treated Cdrug $0.426 Cost for 1998 inflated to 2005
4
Impact model parameters
Number of woman screened from 1998–1999 N 9713 4
Number of screened women positive with RPR test at ANC clinic from 1998–
1999
696 4
Estimated number of women positive with RPR test at reference laboratory clinicNRPR 1021 Estimated using clinic RPR test
sensitivity (61.8%) and specificity
(99.3%) from cohort study4 21 (see
appendix 2)
Sensitivity of RPR test used at clinic for HTAS SRPR
Hi 86.2% 3, 21
Sensitivity of syphilis POC tests:
For all syphilis Sr 45.8–97.1% See appendix 1 for more details
19
For HTAS Sr
Hi 64.0–100% See appendix 1 for more details19
Specificity of syphilis POC tests Spr 93.4–99.9% See appendix 1 for more details
19
Ratio of TPPA/TPHA to RPR prevalence when tests undertaken in reference
laboratory
h 95.5% (85–107%) Estimated from cohort study3 21
Whether they need centrifuge? dE 0 if use blood, 1 if use serumAll POC tests can be used on blood16
Relative time needed for training compared to RPR test dT 50–100% Assume less training needed for POC
test because simpler to use and
diagnose
Relative number of requisitions needed for POC test dR 10–50% 53 requisitions done per year for RPR.
Less needed for POC tests because no
fridge needed and stable for .1
year16
Relative amount of wastage dW 0–5% No specific data
ANC, antenatal clinic; HTAS, high titre active syphilis; POC, point-of-care; RPR, rapid plasma reagin; TPHA, Treponema pallidum haemagglutination assay; TPPA,
Treponema pallidum particle agglutination assay.
To view appendices 1 and 2 visit the STI website— http://www.stijournal.com/supplemental
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average more cost-effective than RPR, 49% of the simulations
from the uncertainty analysis suggest otherwise (when used on
blood). This is highlighted in appendix 4, which shows the
incremental (additional) cost and effectiveness of each POC test
relative to the RPR test from the uncertainty analysis. The plots
show that there is substantial uncertainty in the incremental
impact of the POC tests, but little variation in the incremental
cost.
When a multi-linear regression analysis was undertaken on
the input and output from each uncertainty analysis, the
variability in the cost-effectiveness of each POC test was found
to be mainly dependent on the uncertainty in the sensitivity of
the POC tests for HTAS. This is illustrated in fig 1, and shows
that for each 5% increase in the sensitivity of the POC tests
there is an approximate $1 improvement in their cost-
effectiveness ratio.
Cost-effectiveness of RPR and POC tests in other settings
A sensitivity analysis was undertaken to explore how the cost-
effectiveness of the RPR or POC test changes between settings.
The results showed that the prevalence of syphilis, past
infections, or RPR false positives has little effect on the
cost-effectiveness projections. In contrast, the cost-effectiveness
of the RPR test worsens by 15% if its sensitivity for HTAS had
been 75% instead of 86%, and by 25–65% if 20–40% of women
had not returned for treatment. In these two scenarios, the
Bioline POC test is highly likely to be more cost-effective than
the RPR test, whereas the other POC tests will only be more
cost-effective if the return rate for treatment is towards the
lower end of the range considered or their sensitivity for HTAS
is towards the high end of the estimated confidence intervals.
In contrast, if the RPR test’s sensitivity for HTAS had been
100% then the cost-effectiveness of the RPR test would have
improved by 14%. In this situation, the POC tests will only be as
cost-effective as the RPR test if they are much cheaper than
their current cost, or not all women return for treatment with
the RPR test. Appendix 6 shows how the cost-effectiveness of
using the RPR or Bioline test changes for these specific scenarios.
Cost thresholds for POC tests
The results in fig 1 show that at current prices only the cheapest
POC test (Bioline) could be as cost-effective as the RPR test in
Mwanza. Indeed, if they are 100% sensitive for HTAS, the cost
of the POC tests has to be less than $0.63 for their cost-
effectiveness to be similar to the RPR test. However, if the
sensitivity of the POC tests is only 85%, then even the Bioline
test would have to be at least $0.13 cheaper than its current cost
($0.47). Appendix 5 shows the threshold costs for each POC
test, and shows that for a specific HTAS sensitivity, the cost-
thresholds only vary by $0.04 between tests and whether they
are used on blood or serum.
For different POC and RPR test sensitivities and return rates,
fig 2 shows the lower-bound cost-thresholds for the POC tests.
The dashed line signifies the projections for Mwanza (RPR test
sensitivity for HTAS = 86%). The figure shows that for every 5%
decrease in the return rate or sensitivity of the RPR test for
HTAS, the cost of a POC test can be about $0.10 greater. In
contrast, for every 5% decrease in the sensitivity of the POC test
for HTAS, its cost has to decrease by about $0.12.
DISCUSSION
This study compared the likely cost-effectiveness of four
syphilis POC tests against the cost-effectiveness of the RPR
test in an antenatal syphilis screening intervention in Mwanza,
Tanzania. Uncertainty in the POC test sensitivity for HTAS
resulted in uncertainty in their likely impact and cost-
effectiveness. Despite this uncertainty, the model projections
suggest that all the POC tests, except Determine, are likely to
result in marginally greater impact than the RPR test due to
their higher HTAS sensitivity in this setting. However, at
Table 2 Cost-effectiveness per DALY saved (2005 US$) of each POC test using Tanzanian life expectancy. Uncertainty bounds are
in brackets
POC test
Test done on serum* Test done on blood
DALYs saved Cost/DALY saved
% of RPR cost/DALY
saved DALYs saved Cost/DALY saved
% of RPR cost/DALY
saved
RPR test 1321 12.0 100%
Determine
(Abbot)
1316 (746–1532) 17.0 (14.3–29.5) 141% (119–247%) 1309 (681–1529) 16.8 (14.0–31.5) 140% (117–263%)
Visitect
(Omega)
1373 (877–1532) 14.3 (12.6–22.4) 119% (105–187%) 1373 (935–1531) 14.1 (12.4–20.7) 118% (104–173%)
Syphcheck
(Qualpro)
1390 (887–1531) 14.1 (12.6–21.9) 118% (105–183%) 1397 (972–1532) 13.9 (12.5–19.7) 116% (104–164%)
Bioline
(Standard)
1430 (1127–1532) 11.8 (10.9–15.0) 99% (91–125%) 1372 (914–1530) 12.1 (10.7–18.1) 101% (89–151%)
*The impact and cost-effectiveness estimates for when the POC test is done on serum use sensitivity and specificity estimates derived from the reference laboratory.
 The impact and cost-effectiveness estimates for when the POC test is done on blood use sensitivity and specificity estimates derived from antenatal clinic.
DALY, disability-adjusted life year; POC, point-of-care; RPR, rapid plasma reagin.
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Figure 1 Projected cost-effectiveness (per disability-adjusted life year
(DALY) saved in 2005 US$) of each syphilis point-of-care (POC) test for
different assumptions about their sensitivity for high titre active syphilis
(HTAS). The projections assume that the tests are used on blood in an
antenatal clinic setting and the bounds refer to the variability due to the
uncertainty in the other parameters. CE, cost-effectiveness; RPR, rapid
plasma reagin.
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current prices, only the Bioline test may be as cost-effective, and
will at best result in an 11% improvement in the cost-
effectiveness ratio (at 100% HTAS sensitivity). In contrast, the
other POC tests need to be 33–50% cheaper to be as cost-
effectiveness as the RPR test. For example, if the POC tests are
95% sensitive for HTAS, then they would need to cost,$0.54 per
test (if used on blood), whereas for each 5% reduction in
sensitivity the price of the POC tests need to drop by about $0.10.
These results illustrate that only Bioline can be considered as a
replacement for RPR in Mwanza, and highlights the importance
of HTAS sensitivity on threshold prices for POC tests.
The antenatal clinic in Mwanza was well equipped with a
centrifuge, electric shaker and refrigerator. This meant the RPR
test could be done relatively quickly on-site, and all women
were tested and treated during the same visit. In other less well
equipped clinics, or in settings without electricity, blood
samples are sometimes sent to central laboratories for testing,
or are left to stand to separate the serum needed for RPR
testing. These delays can result in up to 20–40% of screened
women not receiving treatment.7 10–12 In these settings the
model projects the cost-effectiveness of using the RPR test
could worsen by 25% and 65% for an 80% and 60% return rate,
respectively. Even at the cheaper of these cost-effectiveness
levels, it is highly likely that the Bioline test will be more cost-
effective than the RPR test, whereas the Syphcheck and Visitect
tests will be more cost-effective if their sensitivity to HTAS is
greater than 80%. This illustrates the usefulness of POC tests in
resource poor settings, because they can be used on whole
blood, and do not require electrical equipment.
The sensitivity of the RPR test used at the Mwanza clinic was
quite low for HTAS (86.2%). Had the intervention achieved
100% sensitivity, the intervention’s cost-effectiveness would
have improved by 14%, and none of the POC tests would have
been more cost-effective at current prices. This illustrates that
the RPR test is likely to be the best choice in settings with good
facilities and well trained staff. However, the conditions for
undertaking the RPR test will be far from perfect in many
clinics in developing countries.10 13 If the RPR test had been 75%
sensitive for HTAS,14 then the Bioline test would be more cost-
effective if its HTAS sensitivity is above 80%, whereas the
Visitect and Syphcheck tests would need an HTAS sensitivity
above 95%. All the POC tests would be more cost-effective if the
RPR test had a HTAS sensitivity below 65%. This again
illustrates the benefit of using POC tests in settings that are
not ideal for the RPR test.
Another important question is whether our results would
vary in other epidemiological settings. However, although this
analysis showed that the cost-effectiveness of each test is
highly dependent on syphilis prevalence, the relative cost-
effectiveness of the POC tests compared to RPR is not. This
implies that syphilis prevalence should not be used as a
decision criterion for using either type of test.
One weakness of current POC tests is that individuals remain
positive after resolution of infection. This means their use could
result in substantial over-treatment, especially if syphilis
treatment has been occurring.17 18 24 25 Similarly biological false
positive RPR results can also result in substantial over-
treatment.17 18 23 However, apart from the possible negative
social implications of wrongly diagnosing women for syphilis,26
this analysis showed that the effect of over-treatment on the
cost-effectiveness of either type of test is small because
treatment costs are relatively small. For example, if the
prevalence of resolved infections was fourfold greater than in
Mwanza, then the cost-effectiveness of using POC tests only
worsens by 3%. This illustrates that the prevalence of biological
false positives or resolved infections is unlikely to be important
in deciding whether to use POC or RPR tests in a particular
setting, except if there are major negative implications
associated with wrongly diagnosing women. However, because
of the substantial over-treatment that can occur with either
test, care should always be taken in emphasising that the test is
Key messages
N More studies need to be done evaluating the sensitivity of
point-of-care (POC) tests for high titre active syphilis
(HTAS). However, if the limited data suggesting POC tests
have a high sensitivity for HTAS are correct, POC tests
could result in similar numbers of ‘‘at risk’’ women being
treated for maternal syphilis.
N Unless the cost of available POC tests reduces to below
US$0.63, the rapid plasma reagin (RPR) test is likely to
be a more cost-effective option for maternal syphilis
screening interventions in well equipped settings with well
trained staff such as Mwanza.
N In settings where not all screened women are treated
because of delays between testing and treatment, or the
RPR test has a lower sensitivity for high titre active syphilis
(HTAS) than in Mwanza, then POC tests could improve
the cost-effectiveness of maternal syphilis screening
interventions. This is likely to include many rural or
resource-poor settings.
N Because POC tests are not dependent on expensive
equipment or electricity, they could enable the scaling up
of maternal syphilis interventions to settings that would
otherwise be hard to reach due to operational difficulties
in using the RPR test.
Figure 2 Threshold costs (in 2005 US$) for POC test to be as cost-effective
as RPR test for different sensitivities of POC and RPR test for HTAS and
different return rates for treatment with the RPR test. Dashed line signifies
the cost thresholds for Mwanza. HTAS, high titre active syphilis;
POC, point-of-care; RPR, rapid plasma reagin.
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being used for screening and would normally require con-
firmatory testing, but given the potential threat for the unborn
child treatment is given even when this cannot be done. This is
especially important when treatment strategies also invite
partners for treatment.
CONCLUSION
More studies need to be done evaluating the sensitivity of POC
tests for HTAS. However, if the limited data suggesting POC
tests have a high sensitivity for HTAS are correct, POC tests
should be considered as an alternative to the RPR test in many
settings. In Mwanza, the Bioline, Visitect and Syphcheck tests
are all likely to have resulted in more ‘‘at risk’’ women being
treated, and the Bioline test would have cost a similar amount
per DALY saved. Indeed, the Bioline test is likely to be more
cost-effective than the RPR test in settings where either not all
screened women are treated, or the RPR test has a lower
sensitivity for HTAS than in Mwanza. This is likely to include
many settings where maternal syphilis screening currently
takes place,5 6 10–13 15 22 and specifically many rural or resource-
poor settings. Alternatively, the RPR test is likely to be a better
option in well equipped settings with well trained staff. For the
other POC tests to be as cost-effective as the RPR test and
competitive with the Bioline test, they need to be at least as
cheap as the Bioline test or highly sensitive for HTAS. Lastly,
because POC tests are not dependent on expensive equipment
or electricity, they could enable the scaling up of maternal
syphilis interventions to settings that would otherwise be hard
to reach due to operational difficulties in using the RPR test.
This is an important advantage of POC tests, and their use in
low coverage areas should be seen as an important priority for
health providers.
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